Business Wire

ABP Publishing Reports the Sales Increased 60% In 2020

Share

The annual reports inform that the production and, thus, sales grew significantly whereas the audience preferences veered round into health and relations fields.

Besides, in 2021, the publishing house plans to acquire new genres in non-fiction and cooperate with new promising authors, retailers, and markets.

Although the circumstances made the editorial team work remotely, the number of published audiobooks did not diminish but increased. In particular, 109 books were recorded in 2020. The company published, among others, such bestsellers as Educated by Tara Westover, Flow by Mihaly Csikszentmihalyi, and Talking to Strangers by Malcolm Gladwell (German); Money. Master The Game by Tony Robbins, Bad Blood by John Carreyrou, and Big Magic by Elizabeth Gilbert (French); Atomic Habits by James Clear, Outliers by Malcolm Gladwell, and Becoming Supernatural by Joe Dispenza (Italian).

Additionally, in 2020, the publishing house started acquiring new languages producing books in Swedish, Turkish, Spanish, Norwegian, and Japanese.

The increase in production led to the rise in sales, logically. The sales report for 2020 showed a growth of 60 per cent, comparing to 2019. As mentioned, the listeners downloaded more books about health and relations, which is evidence of a slight change in audience preferences.

Further, in 2020, ABP Publishing worked on its ABP Verlag, ABP Editions, and ABP Editore brands. Every subsidiary got a new logotype and site. Moreover, each of the ABP Publishing books can be associated with the publisher, thanks to the standardised cover design.

Following the listeners' interests, in 2021, ABP Publishing plans to release audiobooks in fields and topics the company did not work with before, for instance, publicism and fiction. As an example, the German division has already published Demi Moore's autobiography while the French department is preparing the timeless classic bestseller Atlas Shrugged by Ayn Rand. Besides, the publisher increases the number of titles in relationship and parenting and popular science genres. It is important that despite the growing number of titles, the company keeps the high quality of audiobooks, practising an attentive approach to the voice-overs cast and music and dramatic audiobooks style.

Nevertheless, in the coming years, most publishers in the digital field will face the expansion of subscription and streaming model of distribution. The listeners appreciated the profit of the unlimited access to audiobooks, whereas the publishing houses are switching to a new reality reluctantly. Anyway, all the publishing companies will have to find a balance between listeners' wishes and desirable income. ABP Publishing believes that the changes will be advantageous for all the market participants and cause the better quality of published audiobooks in competitive terms.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Viktoria Salnikova
Chief Editor
+7(968)973-62-79
editor@abp-publishing.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release

Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye